Macquarie Group
AUGX

Macquarie Group’s Augmedix, Inc. Common Stock AUGX Stock Holding History

Macquarie Group’s Portfolio AUGX Stock Details AUGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-856
Closed -$4 – 2189
2024
Q1 		$4 Buy
+856
New +$3.83K ﹤0.01% 1827

Other funds holding AUGX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Macquarie Group's AUGX Position: Q2 2024 in Review

Macquarie Group sold out of Augmedix, Inc. Common Stock (AUGX) in Q2 2024, closing a stake of 856 shares — an estimated $4 sold.

Macquarie Group first reported a position in AUGX in Q1 2024 and held it in 1 quarter. The position peaked at $4 in Q1 2024. 52 funds tracked by Wall St. Rank hold AUGX as of Q2 2024.

  • Macquarie Group reported no remaining Augmedix, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 856 Augmedix, Inc. Common Stock shares in Q2 2024, an estimated $4.
  • Macquarie Group first reported a position in Augmedix, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Augmedix, Inc. Common Stock position peaked at $4 in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.